Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-09-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于公司2021年限制性股票激励计划第一个解除限售期及暂缓部分第一个解除限售期解除限售条件成就之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the fulfillment of conditions for the first unlocking period of a 2021 restricted stock incentive plan by a company. It details the legal compliance, procedures followed, and the status of stock unlocking for specific executives and directors. The document is not a financial report, earnings release, or management discussion, but a legal certification related to stock incentive plan implementation. It is a standalone legal opinion on a corporate action, not a general regulatory filing or announcement. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document and does not fall under other more specific categories like Remuneration Information or Board/Management Information.
2022-09-02 Chinese
国浩律师（深圳）事务所关于公司2019年股票期权激励计划第三个行权期可行权之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the third exercise period of a 2019 stock option incentive plan for a company. It details the legal compliance, approvals, authorizations, and conditions met for the stock option exercise. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a specific corporate action (stock option exercise). It is not a simple announcement or certification but a detailed legal opinion. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance document related to securities law and corporate governance, not a financial report or announcement of voting results or capital changes. The document length (7589 characters) and content confirm it is not a brief announcement or proxy material but a substantive legal opinion letter.
2022-09-02 Chinese
第四届董事会第四十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 40th meeting of the 4th Board of Directors of the company. It details the approval of stock option incentive plans and restricted stock incentive plans, including voting results and independent director opinions. The content focuses on board decisions and management matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or earnings release. The document is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 1761 characters, consistent with a meeting resolution announcement rather than a full report.
2022-09-02 Chinese
关于 2017 年股票期权激励计划预留授予股票期权第三个行权期可行权的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the exercise of stock options under the company's 2017 stock option incentive plan. It includes information about the number of options exercisable, the exercise price, the conditions met for the exercise period, approvals by the board and supervisory committee, independent director opinions, legal opinions, and financial advisor opinions. The document is not a full financial report but rather a corporate announcement about stock option exercises and related corporate governance matters. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not a simple brief announcement but a detailed disclosure about stock option exercise rights and conditions. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-09-02 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于公司2021年限制性股票激励计划第一个解除限售期及暂缓部分第一个解除限售期解除限售条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2021 Restricted Stock Incentive Plan of the company. It details the approval procedures, conditions met for lifting restrictions on stock, performance assessments, and the number of shares eligible for release from restrictions. The document includes legal references, board and supervisory meetings, and independent opinions. It is a detailed advisory report on the stock incentive plan's progress and compliance, not a general annual or quarterly financial report, nor an earnings release or capital update. It is not a proxy solicitation or voting result announcement. The document is a standalone advisory report related to a specific stock incentive plan and its conditions, which fits the category of Audit Report / Information (AR) as it involves independent financial advisor's verification and opinions on compliance and conditions achievement. The document length is sufficient and contains substantive content, not just an announcement or certification. Therefore, the best fitting classification is AR (Audit Report / Information). FY 2021
2022-09-02 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于公司2019年第二期股票期权激励计划第二个行权期行权条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report regarding the achievement of exercise conditions for the second exercise period of the 2019 second stock option incentive plan of the company 健帆生物科技集团股份有限公司. It details the approval procedures, conditions met, number of stock options exercisable, and the advisor's verification opinion. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a detailed advisory report related to stock option incentive plans and their exercise conditions, which fits the category of Audit Report / Information (AR) as it involves verification and compliance with regulatory and company rules regarding stock option plans. The document length (7333 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-09-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.